Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Medical malpractice
Represented a widower after his wife died due to healthcare negligence.  The case resulted in one of the largest medical malpractice settlements ever more
Innovative strategic alliance for Acuity Brands Lighting Inc.
Represented Acuity Brands Lighting Inc, one of the world's leading providers of lighting fixtures and related products and services, in connection more
Product liability of an automotive manufacturer
Represented German automotive manufacturer in first-collision, crashworthiness, and failure-to-warn cases in courts across the country. Also defended more
Energy advice to a Swedish governmental body
Represented a Swedish governmental body on regulation of use of electricity grid.  The firm also negotiated with several industrial partners, more